Celcuity Inc.

CELC · Nasdaq · United States

Share price · CELC

$55.60-37.64 (-40.37%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.0M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CELC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026+6.5%
  2. 14 Oct 2026-5.2%
  3. 7 Oct 2026-7.7%
  4. 15 Jul 2026-17.6%
  5. 2 Jun 2026-25.7%
  6. 14 May 2026+8.2%
  7. 4 May 2026+15.4%
  8. 24 Apr 2026+6.6%

    Nothing announced by CELC that day or the session before.

  9. 23 Apr 2026-7.2%

    Nothing announced by CELC that day or the session before.

  10. 21 Apr 2026+5.0%

Share of unusual movement by asset

For each asset, the share of CELC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Gedatolisib (Revtorpyk)
events and moves
96%
Other company news (earnings, financing, releases naming no asset)—81%
Sessions with no dated event—13%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Gedatolisib(Revtorpyk)
Approved
PI3K (class I isoforms) and mTORC1/mTORC2Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Gedatolisib · RevtorpykPhase 1/2mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease …
Est. primary completion 2028-01 · NCT06190899 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Gedatolisib · RevtorpykPhase 3Breast Cancer
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 August 2026Filing submittedGedatolisibCelcuity submits an sNDA for gedatolisib (REVTORPYK) in PIK3CA-mutant HR+/HER2- advanced breast cancer (announced 2026-08-26)
US, FDA · Celcuity · Source ↗
14 July 2026ApprovalGedatolisibFDA approves REVTORPYK (gedatolisib) in PIK3CA wild-type HR+/HER2- breast cancer
US, FDA · Source ↗
January 2026Filing acceptedGedatolisibFDA accepts the gedatolisib NDA
US, FDA · Source ↗
January 2026Priority reviewGedatolisibFDA grants Priority Review to the gedatolisib NDA (PDUFA July 17, 2026)
US, FDA · Source ↗
17 November 2025Filing submittedGedatolisibCelcuity completes NDA submission for gedatolisib
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$38M$178M+ $465M short-term inv.$73M-$66M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$31M$182M+ $572M short-term inv.$79M-$55M operating cash flowreport ↗
2026-Q1—$33M$145M+ $242M short-term inv.$53M-$55M operating cash flowreport ↗
2025-Q3—$35M$74M+ $381M short-term inv.$44M-$45M operating cash flowreport ↗
2025-Q2—$40M$46M+ $122M short-term inv.$45M-$36M operating cash flowreport ↗
2025-Q1—$32M$16M+ $189M short-term inv.$37M-$36M operating cash flowreport ↗
2024-Q3—$28M$13M+ $251M short-term inv.$30M-$21M operating cash flowreport ↗
2024-Q2—$23M$30M+ $253M short-term inv.$24M-$18M operating cash flowreport ↗
2024-Q1—$21M$31M+ $146M short-term inv.$22M-$17M operating cash flowreport ↗
2023-Q3—$17M$26M+ $108M short-term inv.$18M-$13M operating cash flowreport ↗
2023-Q2—$14M$32M+ $114M short-term inv.$15M-$9.7M operating cash flowreport ↗
2023-Q1—$11M$34M+ $124M short-term inv.$12M-$13M operating cash flowreport ↗
2022-Q3—$9.6M$57M$11M-$9.3M operating cash flowreport ↗
2022-Q2—$8.4M$67M$10.0M-$11M operating cash flowreport ↗
2022-Q1—$6.7M$78M$7.9M-$5.9M operating cash flowreport ↗
2021-Q3—$5.0M$90M$6.0M-$4.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$145M$166M+ $276M short-term inv.$44M-$153M operating cash flowreport ↗

Celcuity did not disclose revenue for 2025. R&D expense was $145M, up 39.2% YoY from $104.2M, while cash and cash equivalents stood at $165.7M and total cash, cash equivalents, and short-term investments were $441.5M at year-end. The company reported a full-year net loss of $177.0M, or $3.79 per share, compared with a net loss of $111.8M in 2024, and net cash used in operating activities was $153.3M for the full year.

The FDA accepted Celcuity’s New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer and granted Priority Review with a PDUFA goal date of July 17, 2026. Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected in the second quarter of 2026, and results from the PIK3CA wild-type cohort were published in the Journal of Clinical Oncology. Management expects existing cash to finance operations through 2027 and remains on track for a potential commercial launch of gedatolisib in the third quarter of 2026, if approved.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$104M$23M+ $213M short-term inv.$28M-$83M operating cash flowreport ↗
2023-FY—$61M$31M+ $150M short-term inv.$16M-$54M operating cash flowreport ↗
2022-FY—$35M$25M+ $144M short-term inv.$10M-$36M operating cash flowreport ↗
2021-FY—$26M$84M$7.4M-$20M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($327.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-07Furcht Leo · directorOption exercise250$7.60$2KForm 4
2026-10-07Furcht Leo · directorOption exercise (derivative)250——Form 4
2026-10-01GRYSKA DAVID W · directorAward / grant893——Form 4
2026-08-14Hahne Vicky · Chief Financial OfficerAward / grant16,000——Form 4
2026-08-14Sullivan Brian F. · director, Chief Executive OfficerAward / grant80,000——Form 4
2026-08-14Laing Lance G. · director, Chief Science OfficerAward / grant20,000——Form 4
2026-08-14Hahne Vicky · Chief Financial OfficerAward / grant (derivative)10,000——Form 4
2026-08-14Sullivan Brian F. · director, Chief Executive OfficerAward / grant (derivative)120,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 274 reporting institutions held 49.1M shares ($5.4B, 99.9% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP7,915,792$903.5M
2Avoro Capital Advisors LLC3,375,000$385.2M
3PERCEPTIVE ADVISORS LLC3,127,200$356.9M
4RTW INVESTMENTS, LP3,039,621$346.9M
5BlackRock, Inc.2,711,532$309.5M
6NEA Management Company, LLC2,285,561$260.9M
7VANGUARD CAPITAL MANAGEMENT LLC1,782,894$203.5M
8DEERFIELD MANAGEMENT COMPANY, L.P.1,714,000$195.6M
9STATE STREET CORP1,518,705$173.3M
10MORGAN STANLEY1,345,715$153.6M
11Soleus Capital Management, L.P.1,284,378$146.6M
12TANG CAPITAL MANAGEMENT LLC1,050,000$119.8M
13GEODE CAPITAL MANAGEMENT, LLC891,070$101.7M
14TORONTO DOMINION BANK882,758$100.8M
15GOLDMAN SACHS GROUP INC764,975$87.3M